Replies to post #213152 on Biotech Values

[biomaven0]

>>Because the trial has multiple (non-hierarchical) primary endpoints, causing the alpha spend to be divided among them.

I always wonder why a big company would do this rather than do enough work ahead of the trial to try to figure out what the best single endpoint is.